Chiusura precedente | 12,54 |
Aperto | 12,10 |
Denaro | 0,00 x 0 |
Lettera | 0,00 x 0 |
Min-Max giorno | 12,10 - 12,10 |
Intervallo di 52 settimane | 2,87 - 17,80 |
Volume | |
Media Volume | 102.892 |
Capitalizzazione | 16,09M |
Beta (5 anni mensile) | 0,78 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -4,26 |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Ad hoc announcement pursuant to Art. 53 LR Aprocitentan, Idorsia’s oral, dual endothelin receptor antagonist is currently under review with health authorities for the treatment of patients with resistant hypertension.Idorsia will pay Janssen a conditional consideration up to a total cap of CHF 306 millionIdorsia is initiating activities to determine the best approach to maximize the value of aprocitentan. Allschwil, Switzerland – September 6, 2023Idorsia Ltd (SIX: IDIA) today announced that it h
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25, 2023 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2023. Business highlights Transaction with Sosei Heptares: Idorsia sells its Asia Pacific (ex-China) operations – including selected license rights to products – for a total consideration of CHF 400 million.Cost reduction initiative with the target of a reduction in cash-burn at headquarters by approximately 50% expected to become f
Ad hoc announcement pursuant to Art. 53 LR In order to give Idorsia the necessary time to realize commercial success – any funds that are raised must be prioritized on activities to maximize their return in the near-term.The cost reduction initiative is dependent on a full portfolio review, potential out-licensing deals, and an employee representative consultation in Switzerland.The company is launching the initiative with the target of a reduction in cash-burn at headquarters by approximately 5